Eric Drape - 28 Feb 2024 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
01 Mar 2024, 06:45:58 UTC
Prior SEC filing
21 Feb 2024
Next SEC filing
05 Mar 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Dov Bergwerk as attorney-in-fact for Eric Drape

Key filing fact

Eric Drape filed Form 4 for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) on 01 Mar 2024.

Key facts

  • This page summarizes Eric Drape's Form 4 filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 01 Mar 2024, 06:45.

Change

  • Previous filing in this sequence was filed on 21 Feb 2024.
  • Current net transaction value: -$128,734.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TEVA transaction

Ordinary Shares

Options Exercise

Transaction value
Shares
+19,515
Change %
+1951500%
Price
Shares after
19,516
Date
28 Feb 2024
Ownership
Direct
Footnotes
F1, F2
TEVA transaction

Ordinary Shares

Sale

Transaction value
$128,734
Shares
-9,815
Change %
-50%
Price
$13.12
Shares after
9,701
Date
28 Feb 2024
Ownership
Direct
Footnotes
F1, F3, F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TEVA transaction Derivative

Restricted Share Units

Options Exercise

Transaction value
$0
Shares
-19,515
Change %
-100%
Price
$0.000000*
Shares after
0
Date
28 Feb 2024
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
19,515
Exercise price
Footnotes
F2, F6
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 6 footnotes

Footnote F1

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Footnote F2

Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Footnote F3

The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023.

Footnote F4

Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

Footnote F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.01 to $13.19, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Footnote F6

Restricted share units were granted on February 28, 2020 with 19,514 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023, and 19,515 vested on February 28, 2024.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .